Abstract is: Neuropsychiatric systemic lupus erythematosus or NPSLE refers to the neurological and psychiatric manifestations of systemic lupus erythematosus. SLE is a disease in which the immune system attacks the body's own cells and tissues. It can affect various organs or systems of the body. It is estimated that over half of people with SLE have neuropsychiatric involvement.
| P7807 | ICD-11 ID (Foundation) | 1552156400 |
| P486 | MeSH descriptor ID | D020945 |
| P672 | MeSH tree code | C10.114.875.850 |
| C10.228.140.300.850.750 | ||
| C10.228.140.430.550.500 | ||
| C10.228.228.245.550.500 | ||
| C10.228.228.570.450 | ||
| C14.907.253.946.850 | ||
| C14.907.940.907.850 | ||
| C17.300.480.750 | ||
| C20.111.258.962.900 | ||
| C20.111.590.750 | ||
| C01.207.245.550.500 | ||
| C01.207.570.450 | ||
| C10.586.250.550.500 | ||
| C10.586.625.500.500 | ||
| P6366 | Microsoft Academic ID | 2780488172 |
| P1995 | health specialty | immunology | Q101929 |
| cardiology | Q10379 | ||
| neurology | Q83042 | ||
| rheumatology | Q327657 |
| Q113384877 | A Case of Neuropsychiatric Systemic Lupus Erythematosus With Hair Loss as the First Diagnostic Symptom |
| Q37235501 | A Comprehensive Rehabilitation Approach in a Patient With Serious Neuropsychiatric Systemic Lupus Erythematosus |
| Q90786670 | A De Novo Frameshift Mutation in TNFAIP3 Impairs A20 Deubiquitination Function to Cause Neuropsychiatric Systemic Lupus Erythematosus |
| Q38615244 | A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. |
| Q35760387 | A multimodal MRI approach to identify and characterize microstructural brain changes in neuropsychiatric systemic lupus erythematosus |
| Q91021327 | Abnormal amplitude of low frequency fluctuation and functional connectivity in non-neuropsychiatric systemic lupus erythematosus: a resting-state fMRI study |
| Q47912052 | Abnormal brain diffusivity in patients with neuropsychiatric systemic lupus erythematosus |
| Q99576563 | Absence of neuronal autoantibodies in neuropsychiatric systemic lupus erythematosus |
| Q82132749 | Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis |
| Q34240254 | Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes |
| Q94459165 | Advanced neuroimaging in neuropsychiatric systemic lupus erythematosus |
| Q92371755 | Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus |
| Q52026140 | Alterations of cerebral glucose metabolism indicate progress to severe morphological brain lesions in neuropsychiatric systemic lupus erythematosus. |
| Q37545475 | Alterations of white matter structural networks in patients with non-neuropsychiatric systemic lupus erythematosus identified by probabilistic tractography and connectivity-based analyses |
| Q48707354 | An fMRI study of the motor system in patients with neuropsychiatric systemic lupus erythematosus |
| Q44396880 | Analysis of JC virus DNA in NPSLE patients treated with different immunomodulatory agents |
| Q103743126 | Anti-MDA5 antibody-positive juvenile dermatomyositis overlap with neuropsychiatric systemic lupus erythematosus: a case report |
| Q83135225 | Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus |
| Q33251075 | Anti-endothelial antibodies and neuropsychiatric systemic lupus erythematosus |
| Q84940460 | Anti-ribosomal P protein antibodies and neuropsychiatric systemic lupus erythematosus: cross-sectional vs. prospective studies |
| Q44583325 | Antibodies in patients with neuropsychiatric systemic lupus erythematosus |
| Q47784251 | Antibodies to microtubule-associated protein 2 in patients with neuropsychiatric systemic lupus erythematosus |
| Q50755682 | Antibodies to microtubule-associated protein-2 in the cerebrospinal fluid are a useful diagnostic biomarker for neuropsychiatric systemic lupus erythematosus. |
| Q67482136 | Antiganglioside antibodies in patients with neuropsychiatric systemic lupus erythematosus |
| Q68388867 | Antineurofilament antibody evaluation in neuropsychiatric systemic lupus erythematosus. Combination with anticardiolipin antibody assay and magnetic resonance imaging |
| Q81114363 | Antineuronal antibodies and electroneurophysiological studies in pediatric patients with neuropsychiatric systemic lupus erythematosus |
| Q41949525 | Antineuronal antibodies and neuropsychiatric systemic lupus erythematosus |
| Q48473651 | Antineuronal antibodies in neuropsychiatric systemic lupus erythematosus |
| Q73685453 | Antiphospholipid antibodies and the antiphospholipid syndrome. Clinical relevance in neuropsychiatric systemic lupus erythematosus |
| Q81226290 | Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus |
| Q36227162 | Assessing "occult" cervical cord damage in patients with neuropsychiatric systemic lupus erythematosus using diffusion tensor MRI. |
| Q87226082 | Association between anti-U1 ribonucleoprotein antibodies and inflammatory mediators in cerebrospinal fluid of patients with neuropsychiatric systemic lupus erythematosus |
| Q54527697 | Association between serum IgG antibodies to recombinant ribosomal P0 fusion protein and neuropsychiatric systemic lupus erythematosus. |
| Q46919830 | Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus |
| Q98943826 | Association of anti-NR2 and U1RNP antibodies with neurotoxic inflammatory mediators in cerebrospinal fluid from patients with neuropsychiatric systemic lupus erythematosus |
| Q93491570 | Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus |
| Q48934171 | Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus |
| Q38815472 | Association of anti-triosephosphate isomerase antibodies with aseptic meningitis in patients with neuropsychiatric systemic lupus erythematosus. |
| Q40969306 | Association of antibodies to the NR1 subunit of N-methyl-D-aspartate receptors with neuropsychiatric systemic lupus erythematosus |
| Q34947235 | Association of antiphosphatidylserine/prothrombin antibodies with neuropsychiatric systemic lupus erythematosus |
| Q39995970 | Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus |
| Q48465933 | Association of global brain damage and clinical functioning in neuropsychiatric systemic lupus erythematosus |
| Q82777758 | Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjögren's syndrome |
| Q90338344 | Autoantibodies associated with neuropsychiatric systemic lupus erythematosus: the quest for symptom-specific biomarkers |
| Q37592934 | Autoantibodies to NR2A Peptide of the Glutamate/NMDA Receptor in Patients with Seizure Disorders in Neuropsychiatric Systemic Lupus Erythematosus |
| Q46645713 | Autoantibody-mediated neuroinflammation: pathogenesis of neuropsychiatric systemic lupus erythematosus in the NZM88 murine model |
| Q91567432 | Basal ganglia calcifications (Fahr's syndrome): related conditions and clinical features |
| Q93094695 | Bilateral Orbital Compartment Syndrome Preceding Cerebellar Herniation in Neuropsychiatric Systemic Lupus Erythematosus |
| Q87286089 | Biologic therapies in patients with neuropsychiatric systemic lupus erythematosus |
| Q34478805 | Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children |
| Q91581255 | Blood-brain barrier disruption and neuroinflammation as pathophysiological mechanisms of the diffuse manifestations of neuropsychiatric systemic lupus erythematosus |
| Q31122956 | Brain diffusivity in patients with neuropsychiatric systemic lupus erythematosus with new acute neurological symptoms |
| Q34307190 | Brain single-photon emission tomography with 99mTc-HMPAO in neuropsychiatric systemic lupus erythematosus: relations with EEG and MRI findings and clinical manifestations |
| Q47801743 | Brain white matter structural networks in patients with non-neuropsychiatric systemic lupus erythematosus |
| Q104142940 | Broad Learning Enhanced 1H-MRS for Early Diagnosis of Neuropsychiatric Systemic Lupus Erythematosus |
| Q39906091 | C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus |
| Q53173444 | Central nervous system tuberculosis: mimicking neuropsychiatric systemic lupus erythematosus. |
| Q91964114 | Cerebral blood flow abnormalities in neuropsychiatric systemic lupus erythematosus |
| Q38400541 | Cerebral venous thrombosis as a complication of neuropsychiatric systemic lupus erythematosus |
| Q48222363 | Cerebrospinal fluid immunoglobulins and neuronal antibodies in neuropsychiatric systemic lupus erythematosus and related conditions |
| Q52029738 | Cerebrospinal fluid interleukin-6, prostaglandin E2 and autoantibodies in patients with neuropsychiatric systemic lupus erythematosus and central nervous system infections. |
| Q58190179 | Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus |
| Q39043287 | Challenges of Diagnosing Cognitive Dysfunction With Neuropsychiatric Systemic Lupus Erythematosus in Childhood. |
| Q48892674 | Changes in White Matter Microstructure Suggest an Inflammatory Origin of Neuropsychiatric Systemic Lupus Erythematosus. |
| Q46128535 | Changes in regional brain morphology in neuropsychiatric systemic lupus erythematosus |
| Q56978208 | Characterization of discriminant human brain antigenic targets in neuropsychiatric systemic lupus erythematosus using an immunoproteomic approach |
| Q86205290 | Circulating microparticles in neuropsychiatric systemic lupus erythematosus |
| Q36766114 | Classification criteria for neuropsychiatric systemic lupus erythematosus: do they need a discussion? |
| Q48184062 | Clinical Image: posterior reversible encephalopathy syndrome as a severe manifestation of neuropsychiatric systemic lupus erythematosus |
| Q84782622 | Clinical analysis of anti-NR2 glutamate receptor antibodies and interleukin-6 with neuropsychiatric systemic lupus erythematosus |
| Q48160395 | Clinical analysis of cerebrospinal fluid interleukin-6 in neuropsychiatric systemic lupus erythematosus. |
| Q73028043 | Clinical images: Neuropsychiatric systemic lupus erythematosus |
| Q90606223 | Clinical manifestations of neuropsychiatric systemic lupus erythematosus: a single-center study from West Pomerania Province in Poland |
| Q57791846 | Clinical significance of anti-DNA/N-methyl-D-aspartate receptor 2 antibodies in de novo and post-steroid cases with neuropsychiatric systemic lupus erythematosus |
| Q37098873 | Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus |
| Q90280713 | Clinical, neuroimaging and immunological phenotype of South African neuropsychiatric systemic lupus erythematosus patients |
| Q87489536 | Cluster analysis of an array of autoantibodies in neuropsychiatric systemic lupus erythematosus |
| Q31006018 | Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus: preliminary data |
| Q88094564 | Cognitive Impairment in Patients With Neuropsychiatric and Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis |
| Q48133138 | Cognitive and White Matter Tract Differences in MS and Diffuse Neuropsychiatric Systemic Lupus Erythematosus |
| Q34793572 | Cognitive dysfunction in neuropsychiatric systemic lupus erythematosus |
| Q51950330 | Cognitive impairment in systemic lupus erythematosus and neuropsychiatric systemic lupus erythematosus: a population-based neuropsychological study. |
| Q96608451 | Comparative proteomics analysis of plasma protein in patients with neuropsychiatric systemic lupus erythematosus |
| Q51724929 | Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus. |
| Q94475991 | Comprehensive expression profile of long non-coding RNAs in Peripheral blood mononuclear cells from patients with neuropsychiatric systemic lupus erythematosus |
| Q98179299 | Correction to: A De Novo Frameshift Mutation in TNFAIP3 Impairs A20 Deubiquitination Function to Cause Neuropsychiatric Systemic Lupus Erythematosus |
| Q46625170 | Correlation of magnetization transfer ratio histogram parameters with neuropsychiatric systemic lupus erythematosus criteria and proton magnetic resonance spectroscopy: association of magnetization transfer ratio peak height with neuronal and cognit |
| Q33547420 | Cortical thickness and subcortical gray matter reductions in neuropsychiatric systemic lupus erythematosus |
| Q38815434 | Cortical thickness reductions associate with abnormal resting-state functional connectivity in non-neuropsychiatric systemic lupus erythematosus |
| Q37416483 | Corticobulbar Tract Involvement in Neuropsychiatric Systemic Lupus Erythematosus: A Case Report |
| Q38660157 | Current concepts of neuropsychiatric systemic lupus erythematosus (NP-SLE) |
| Q40183545 | Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study |
| Q33628713 | Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus |
| Q36117913 | Decreased Coupling Between Functional Connectivity Density and Amplitude of Low Frequency Fluctuation in Non-Neuropsychiatric Systemic Lupus Erythematosus: a Resting-Stage Functional MRI Study |
| Q55234314 | Definition of NPSLE: Does the ACR Nomenclature Still Hold? |
| Q73202418 | Detection of cerebral involvement in patients with active neuropsychiatric systemic lupus erythematosus by the use of volumetric magnetization transfer imaging |
| Q48446436 | Detection of cerebral microvascular lesions using 7 T MRI in patients with neuropsychiatric systemic lupus erythematosus |
| Q38262100 | Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus |
| Q97567603 | Developmental process in diffuse psychological/neuropsychiatric manifestations of neuropsychiatric systemic lupus erythematosus |
| Q34664099 | Diagnosis and management of patients with neuropsychiatric systemic lupus erythematosus (NPSLE). |
| Q38006815 | Diagnostic criteria for neuropsychiatric systemic lupus erythematosus: the results of a consensus meeting. The Ad Hoc Neuropsychiatric Lupus Workshop Group |
| Q38617289 | Differences between central nervous system infection and neuropsychiatric systemic lupus erythematosus in patients with systemic lupus erythematosus |
| Q113189895 | Different phenotypes of neuropsychiatric systemic lupus erythematosus are related to a distinct pattern of structural changes on brain MRI |
| Q42102188 | Differential activation mechanisms of serum C5a in lupus nephritis and neuropsychiatric systemic lupus erythematosus |
| Q91673179 | Differential expression of antibodies to NMDA receptor in anti-NMDA receptor encephalitis and in neuropsychiatric systemic lupus erythematosus |
| Q33643779 | Diffusion tensor imaging in neuropsychiatric systemic lupus erythematosus |
| Q40234720 | Diffusion tensor imaging in patients with acute onset of neuropsychiatric systemic lupus erythematosus: a prospective study of apparent diffusion coefficient, fractional anisotropy values, and eigenvalues in different regions of the brain |
| Q89293199 | Distinct regional brain atrophy pattern in multiple sclerosis and neuropsychiatric systemic lupus erythematosus patients |
| Q50962643 | Distinguishing the cerebrospinal fluid cytokine profile in neuropsychiatric systemic lupus erythematosus from other autoimmune neurological diseases. |
| Q44522994 | Drug alternatives in therapy of neuropsychiatric systemic lupus erythematosus (NPSLE) |
| Q48287566 | Dysfunctional cortico-basal ganglia-thalamic circuit and altered hippocampal-amygdala activity on cognitive set-shifting in non-neuropsychiatric systemic lupus erythematosus |
| Q30886868 | EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres |
| Q50311759 | Echolalia as a novel manifestation of neuropsychiatric systemic lupus erythematosus. |
| Q64118295 | Editorial: Lupus and the Brain: Advances in Neuropsychiatric Systemic Lupus Erythematosus |
| Q50935842 | Effects of gender on the immune system. Implications for neuropsychiatric systemic lupus erythematosus. |
| Q84335309 | Electroconvulsive therapy for catatonia in neuropsychiatric systemic lupus erythematosus |
| Q41623712 | Elevated levels of soluble fractalkine and increased expression of CX3CR1 in neuropsychiatric systemic lupus erythematosus |
| Q58577181 | Elevation of serum anti-glucose-regulated protein 78 antibodies in neuropsychiatric systemic lupus erythematosus |
| Q73313602 | Enhanced interleukin-6 messenger RNA expression by neuronal cells in a patient with neuropsychiatric systemic lupus erythematosus |
| Q53576675 | Evaluation of average amount of cerebral blood flow measured by brain perfusion index in patients with neuropsychiatric systemic lupus erythematosus. |
| Q42695876 | Evaluation of blood-brain barrier function by quotient alpha2 macroglobulin and its relationship with interleukin-6 and complement component 3 levels in neuropsychiatric systemic lupus erythematosus |
| Q48140270 | Evaluation of cerebral perfusion in patients with neuropsychiatric systemic lupus erythematosus using 123I-IMP SPECT. |
| Q31121775 | Evaluation of magnetic resonance imaging abnormalities in juvenile onset neuropsychiatric systemic lupus erythematosus |
| Q53643335 | Evaluation with MR, perfusion MR and cerebral flowSPECT in NPSLE patients. |
| Q73374707 | Evidence of central nervous system damage in patients with neuropsychiatric systemic lupus erythematosus, demonstrated by magnetization transfer imaging |
| Q83039686 | Expansion of myelin autoreactive CD8+ T lymphocytes in patients with neuropsychiatric systemic lupus erythematosus |
| Q89704380 | Expression of HMGB1 and TLR4 in neuropsychiatric systemic lupus erythematosus patients with seizure disorders |
| Q81484705 | Expression of S100B protein levels in serum and cerebrospinal fluid with different forms of neuropsychiatric systemic lupus erythematosus |
| Q46522767 | Facial and limb angioedema with parotitis and Kikuchi-like necrotizing lymphadenitis preceding neuropsychiatric systemic lupus erythematosus in a young African American male |
| Q33592040 | Fluctuating cognitive abnormalities and cerebral glucose metabolism in neuropsychiatric systemic lupus erythematosus |
| Q48201568 | Fluid Attenuated Inversion Recovery (FLAIR) imaging in neuropsychiatric systemic lupus erythematosus. |
| Q46093073 | Fulminant onset of cerebral immunocomplex vasculitis as first manifestation of neuropsychiatric systemic lupus erythematosus (NPSLE). |
| Q51969419 | Functional MRI in NPSLE patients reveals increased parietal and frontal brain activation during a working memory task compared with controls. |
| Q43644934 | Functional impairments in white matter syndrome of neuropsychiatric systemic lupus erythematosus are similar to those observed in patients with multiple sclerosis |
| Q40102327 | Genetic Variants That Are Associated with Neuropsychiatric Systemic Lupus Erythematosus |
| Q40250622 | Gestational outcomes in patients with neuropsychiatric systemic lupus erythematosus |
| Q33723529 | Glutamate receptor biology and its clinical significance in neuropsychiatric systemic lupus erythematosus |
| Q88061496 | Guillain-Barré syndrome in a patient with neuropsychiatric systemic lupus erythematosus |
| Q90746894 | Identification of Levels of Serum Amyloid A and Apolipoprotein A1 in Serum Proteomic Analysis of Neuropsychiatric Systemic Lupus Erythematosus Patients |
| Q48115666 | Identification of brain lesions in neuropsychiatric systemic lupus erythematosus by magnetic resonance scanning |
| Q31153589 | Identification of novel autoantibodies to GABA(B) receptors in patients with neuropsychiatric systemic lupus erythematosus |
| Q33706809 | Identification of α-tubulin as an autoantigen recognized by sera from patients with neuropsychiatric systemic lupus erythematosus. |
| Q33794818 | Identify biomarkers of neuropsychiatric systemic lupus erythematosus by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry combined with weak cation magnetic beads. |
| Q52726591 | Immune Cell Neurotrophin Production Is Associated with Subcortical Brain Atrophy in Neuropsychiatric Systemic Lupus Erythematosus Patients. |
| Q89923870 | Immunological biomarkers in neuropsychiatric systemic lupus erythematosus: a comparative cross-sectional study from a tertiary care center in South India |
| Q85735172 | Inflammatory profile in cerebrospinal fluid of patients with headache as a manifestation of neuropsychiatric systemic lupus erythematosus |
| Q33579139 | Is immunogenetic susceptibility to neuropsychiatric systemic lupus erythematosus (SLE) different from non-neuropsychiatric SLE? |
| Q38910176 | Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard |
| Q37468127 | Is it relevant to screen young women hospitalized in psychiatric department for neuropsychiatric systemic lupus erythematosus (NPSLE)?: A prospective study of 100 psychiatric inpatients |
| Q90558138 | Is serum TWEAK a useful biomarker of neuropsychiatric systemic lupus erythematosus? |
| Q104740789 | Juvenile Neuropsychiatric Systemic Lupus Erythematosus With Magnetic Resonance Imaging Findings Similar to Acute Necrotizing Encephalopathy |
| Q60046879 | Laboratory and Neuroimaging Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: Where Do We Stand, Where To Go? |
| Q51823798 | Localization of cerebral functional deficits in patients with non-neuropsychiatric systemic lupus erythematosus. |
| Q72296686 | Lymphocyte antigens in neuropsychiatric systemic lupus erythematosus. Relationship of lymphocyte antibody specificities to clinical disease |
| Q40406766 | MRI and 2D-CSI MR spectroscopy of the brain in the evaluation of patients with acute onset of neuropsychiatric systemic lupus erythematosus |
| Q36651573 | Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. |
| Q36341966 | Magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus: current state of the art and novel approaches. |
| Q46909297 | Magnetic resonance imaging of the brain in neuropsychiatric systemic lupus erythematosus |
| Q69594840 | Magnetic resonance imaging versus computed tomographic scanning in neuropsychiatric systemic lupus erythematosus |
| Q36758290 | Magnetic resonance spectroscopy and positron emission tomography scanning in neuropsychiatric systemic lupus erythematosus. |
| Q97548742 | Malignant Catatonia After Antipsychotic and High-Dose Steroid Use in a Teenager With Neuropsychiatric Systemic Lupus Erythematosus |
| Q26774815 | Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives |
| Q44436037 | Markers of acute neuropsychiatric systemic lupus erythematosus: a multidisciplinary evaluation |
| Q51019257 | Memory impairment associated with neurometabolic abnormalities of the hippocampus in patients with non-neuropsychiatric systemic lupus erythematosus. |
| Q92466072 | Montreal Cognitive Assessment and Magnetic Resonance Imaging Identify Cognitive Impairment in Young Patients with Neuropsychiatric Systemic Lupus Erythematosus |
| Q44800972 | Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). |
| Q80845127 | Multisequence magnetic resonance imaging study of neuropsychiatric systemic lupus erythematosus |
| Q46676137 | Mycophenolate mofetil in neuropsychiatric systemic lupus erythematosus |
| Q83465139 | NR2 antibodies in neuropsychiatric systemic lupus erythematosus |
| Q48202982 | Negative symptoms in neuropsychiatric systemic lupus erythematosus. |
| Q33753228 | Neuroimaging in neuropsychiatric systemic lupus erythematosus |
| Q40566254 | Neuropsychiatric Systemic Lupus Erythematosus |
| Q73239513 | Neuropsychiatric Systemic Lupus Erythematosus |
| Q37632131 | Neuropsychiatric Systemic Lupus Erythematosus Involvement: Towards a Tailored Approach to Our Patients? |
| Q57491423 | Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Sphingosine-1-Phosphate Signaling |
| Q38538430 | Neuropsychiatric Systemic Lupus Erythematosus in Children |
| Q37233978 | Neuropsychiatric Systemic Lupus Erythematosus: A Diagnostic Conundrum |
| Q27027588 | Neuropsychiatric lupus: a mosaic of clinical presentations |
| Q33647309 | Neuropsychiatric systemic lupus erythematosus |
| Q73217689 | Neuropsychiatric systemic lupus erythematosus |
| Q59924786 | Neuropsychiatric systemic lupus erythematosus |
| Q50608363 | Neuropsychiatric systemic lupus erythematosus among Nigerians. |
| Q38245655 | Neuropsychiatric systemic lupus erythematosus and cognitive dysfunction: the MRL-lpr mouse strain as a model |
| Q48344728 | Neuropsychiatric systemic lupus erythematosus and the syndrome of inappropriate secretion of antidiuretic hormone: a case report with very late onset systemic lupus erythematosus. |
| Q44667355 | Neuropsychiatric systemic lupus erythematosus associated with anti-phospholipid syndrome, showing massive intracranial calcifications |
| Q46222739 | Neuropsychiatric systemic lupus erythematosus associated with neuroleptic malignant syndrome |
| Q48517160 | Neuropsychiatric systemic lupus erythematosus before and after immunosuppressive treatment: a FDG PET study |
| Q33592162 | Neuropsychiatric systemic lupus erythematosus in elderly people: a case series |
| Q35548444 | Neuropsychiatric systemic lupus erythematosus is associated with imbalance in interleukin 10 promoter haplotypes |
| Q36259188 | Neuropsychiatric systemic lupus erythematosus persists despite attenuation of systemic disease in MRL/lpr mice. |
| Q77805325 | Neuropsychiatric systemic lupus erythematosus presenting as amyotrophic lateral sclerosis |
| Q35009450 | Neuropsychiatric systemic lupus erythematosus presenting as bipolar I disorder with catatonic features |
| Q42539014 | Neuropsychiatric systemic lupus erythematosus reconsidered |
| Q100456366 | Neuropsychiatric systemic lupus erythematosus with cerebellar vasculitis and obstructive hydrocephalus requiring decompressive craniectomy |
| Q48661961 | Neuropsychiatric systemic lupus erythematosus, age, and the neurodevelopmental model: evidence in support of the Weinberger hypothesis |
| Q41590509 | Neuropsychiatric systemic lupus erythematosus. A review of presentation, manifestations, and morbidity in twenty-nine patients |
| Q41590473 | Neuropsychiatric systemic lupus erythematosus. Stress, stroke, and seizures |
| Q35204117 | Neuropsychiatric systemic lupus erythematosus: a diagnostic challenge |
| Q50663884 | Neuropsychiatric systemic lupus erythematosus: association with global disease activity. |
| Q48911695 | Neuropsychiatric systemic lupus erythematosus: correlation of brain MR imaging, CT, and SPECT. |
| Q48636316 | Neuropsychiatric systemic lupus erythematosus: diagnostic and clinical features according to revised ACR criteria. |
| Q83499677 | Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic resonance imaging |
| Q46809434 | Neuropsychiatric systemic lupus erythematosus: magnetic resonance imaging findings and correlation with clinical and immunological features |
| Q48623904 | Neuropsychiatric systemic lupus erythematosus: miles to go before we sleep |
| Q38247180 | Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers |
| Q38202469 | Neuropsychiatric systemic lupus erythematosus: tools for the diagnosis |
| Q114894848 | Noise-Immune Extreme Ensemble Learning for Early Diagnosis of Neuropsychiatric Systemic Lupus Erythematosus |
| Q26796871 | Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus |
| Q47433668 | Novel anti-suprabasin antibodies may contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus |
| Q51894626 | Obsessive-compulsive symptoms as a manifestation of neuropsychiatric systemic lupus erythematosus. |
| Q44795825 | Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality |
| Q48709210 | Participation of the neutrophin brain-derived neurotrophic factor in neuropsychiatric systemic lupus erythematosus |
| Q37556128 | Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers |
| Q72676775 | Pericardial complication of neuropsychiatric systemic lupus erythematosus |
| Q37829378 | Pneumatosis cystoides intestinalis in neuropsychiatric systemic lupus erythematosus with diabetes mellitus: case report and literature review |
| Q40129046 | Predictors of clinical outcomes in patients with neuropsychiatric systemic lupus erythematosus. |
| Q92142461 | Prevalence, outcome and prognostic factors of neuropsychiatric systemic lupus erythematosus: A real world single center study |
| Q91612969 | Primary central nervous system lymphoma in neuropsychiatric systemic lupus erythematosus: case-based review |
| Q51322770 | Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. |
| Q102380242 | Protein A immunoadsorption combination with immunosuppressive therapy improves neuropsychiatric systemic lupus erythematosus: A case report |
| Q40231118 | Protein array autoantibody profiles to determine diagnostic markers for neuropsychiatric systemic lupus erythematosus |
| Q80224146 | Proteomic analysis of autoantibodies in neuropsychiatric systemic lupus erythematosus patient with white matter hyperintensities on brain MRI |
| Q71538132 | Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus |
| Q44579766 | Quantitative imaging of cerebral blood flow using SPECT with 123I-iodoamphetamine in neuropsychiatric systemic lupus erythematosus. |
| Q30887271 | Quantitative magnetic resonance imaging in neuropsychiatric systemic lupus erythematosus. |
| Q30927033 | Recent advances and future perspective in neuroimaging in neuropsychiatric systemic lupus erythematosus |
| Q57331131 | Red ear(s) syndrome associated with child neuropsychiatric systemic lupus erythematosus |
| Q36720077 | Relationship Between Clinical and Immunological Features with Magnetic Resonance Imaging Abnormalities in Female Patients with Neuropsychiatric Systemic Lupus Erythematosus |
| Q43982312 | Relationship between elevated cerebrospinal fluid levels of plasminogen activator inhibitor 1 and neuronal destruction in patients with neuropsychiatric systemic lupus erythematosus |
| Q48967932 | Resolution of neuropsychological and FDG-PET abnormalities in a patient with neuropsychiatric systemic lupus erythematosus |
| Q101210777 | Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis |
| Q104738788 | Role of Serum IL-6 in Neuropsychiatric Systemic lupus Erythematosus |
| Q47596696 | Role of anti-glial fibrillary acidic protein antibodies in the pathogenesis of neuropsychiatric systemic lupus erythematosus should be clarified: comment on the article by Trysberg et al. |
| Q41605531 | Role of autoantibody tests in the diagnostic evaluation of neuropsychiatric systemic lupus erythematosus. |
| Q40572101 | Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus |
| Q95570890 | Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus |
| Q80231561 | Seasonal variation of primary neuropsychiatric systemic lupus erythematosus |
| Q84595899 | Seizure as a presenting symptom in neuropsychiatric systemic lupus erythematosus |
| Q34061733 | Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus |
| Q48079168 | Serum neuron specific enolase - a novel indicator for neuropsychiatric systemic lupus erythematosus? |
| Q42360078 | Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: an alternative to standard of care |
| Q44952579 | Single photon emission computed tomography evaluation for severe neuropsychiatric systemic lupus erythematosus. |
| Q71572970 | Single photon emission computed tomography in neuropsychiatric systemic lupus erythematosus |
| Q74364132 | Single photon emission computed tomography scanning in neuropsychiatric systemic lupus erythematosus |
| Q39934006 | Soluble α-klotho is a potential biomarker associated with neuropsychiatric systemic lupus erythematosus |
| Q55036157 | Some controversies of neuropsychiatric systemic lupus erythematosus. |
| Q48355936 | Spatial Working Memory Impairment in Patients with Non-neuropsychiatric Systemic Lupus Erythematosus: A Blood-oxygen-level Dependent Functional Magnetic Resonance Imaging Study |
| Q91011603 | Striatal Encephalitis in Neuropsychiatric Systemic Lupus Erythematosus |
| Q39384471 | Structural Brain Network Reorganization in Patients with Neuropsychiatric Systemic Lupus Erythematosus. |
| Q39596714 | Sustained normalization of cerebral blood-flow after iloprost therapy in a patient with neuropsychiatric systemic lupus erythematosus |
| Q92966561 | Symptomatic multifocal avascular necrosis in an adolescent with neuropsychiatric systemic lupus erythematosus |
| Q84816559 | TREX1 gene variant in neuropsychiatric systemic lupus erythematosus |
| Q120722627 | Temporal and spatial changes in cerebral blood flow in neuropsychiatric systemic lupus erythematosus: a subtraction brain spect study |
| Q30476952 | The MRL/lpr mouse strain as a model for neuropsychiatric systemic lupus erythematosus |
| Q98240198 | The T Cell Receptor Repertoire in Neuropsychiatric Systemic Lupus Erythematosus |
| Q48258853 | The accuracy of diagnosing neuropsychiatric systemic lupus erythematosus in a series of 49 hospitalized patients |
| Q36722914 | The association between sequential changes in serum antineuronal antibodies and neuropsychiatric systemic lupus erythematosus |
| Q49992628 | The clinical significance of anti- ubiquitin C-terminal hydrolase L1 autoantibodies in the diagnosis of neuropsychiatric systemic lupus erythematosus |
| Q93000138 | The clinical significance of ubiquitin carboxyl hydrolase L1 and its autoantibody in neuropsychiatric systemic lupus erythematosus |
| Q79358177 | The heterogeneity of neuropsychiatric systemic lupus erythematosus is reflected in lack of association with cerebrospinal fluid cytokine profiles |
| Q36729344 | The histopathologic associates of neurometabolite abnormalities in fatal neuropsychiatric systemic lupus erythematosus |
| Q37552138 | The impact and implications of neuropsychiatric systemic lupus erythematosus in adolescents |
| Q64924561 | The potential pathogenetic link between peripheral immune activation and the central innate immune response in neuropsychiatric systemic lupus erythematosus. |
| Q36743360 | The role of autoantibodies in pediatric neuropsychiatric systemic lupus erythematosus |
| Q43897319 | The role of endothelial dysfunction in the pathogenesis of neuropsychiatric systemic lupus erythematosus |
| Q46829495 | The role of measurement of serum autoantibodies in prediction of pediatric neuropsychiatric systemic lupus erythematosus |
| Q74175917 | The role of nuclear medicine in the evaluation of neuropsychiatric systemic lupus erythematosus: comment on the article by Sibbitt et al |
| Q40568409 | The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus |
| Q48227630 | Therapeutic strategies in severe neuropsychiatric systemic lupus erythematosus: experience from a tertiary referral centre |
| Q46781583 | Thyroid hormones and thyroid-stimulating hormone in Egyptian patients with systemic lupus erythematosus: correlation between secondary hypothyroidism and neuropsychiatric systemic lupus erythematosus syndromes |
| Q45245695 | Toll-like receptor 4 gene polymorphism 1196 C/T does not influence the risk of neuropsychiatric systemic lupus erythematosus in Polish population--a preliminary report |
| Q43289398 | Transient brain hyperperfusion detected with I-123 IMP SPECT in a patient with neuropsychiatric systemic lupus erythematosus |
| Q44327878 | Transient panhypogammaglobulinaemia and B-lymphocyte deficiency in a patient with neuropsychiatric systemic lupus erythematosus after immunosuppressive therapy |
| Q47999882 | Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets? |
| Q91463206 | Utility of osteopontin in cerebrospinal fluid as a diagnostic marker for neuropsychiatric systemic lupus erythematosus |
| Q36322289 | Value of multidisciplinary reassessment in attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from the Leiden NPSLE cohort. |
| Q48273560 | Valvular heart disease by transthoracic echocardiography is associated with focal brain injury and central neuropsychiatric systemic lupus erythematosus |
| Q48646312 | Valvular heart disease is associated with nonfocal neuropsychiatric systemic lupus erythematosus. |
| Q45106208 | White matter microstructure and cognition in non-neuropsychiatric systemic lupus erythematosus |
| Q84109872 | Will anti-neuronal antibody biomarkers make neuropsychiatric systemic lupus erythematosus no longer a diagnosis of exclusion? |
| Q81248561 | [Characteristic manifestations of neuropsychiatric systemic lupus erythematosus] |
| Q88970648 | [Contrast-enhanced fluid-attenuated inversion recovery magnetic resonance imaging was useful in detecting inflammation of the meninges in neuropsychiatric systemic lupus erythematosus: a case report] |
| Q92021518 | [Neuropathology of Neuropsychiatric Systemic Lupus Erythematosus (NPSLE)] |
| Q92021503 | [Neuropsychiatric Systemic Lupus Erythematosus: From the Standpoint of Department of Neurology] |
| Q92021511 | [Neuropsychiatric Systemic Lupus Erythematosus: Psychiatric Symptoms] |
| Q92021496 | [Neuropsychiatric Systemic Lupus Erythematosus] |
| Q50771870 | [Neuropsychiatric systemic lupus erythematosus: where are we now?]. |
| Q95453278 | [Neuropsychiatric systemic lupus erythematosus] |
| Q53677239 | [PET scan versus MRI in patients with neuropsychiatric systemic lupus erythematosus. A negative PET scan is unusual] |
| Q92523889 | [Specific markers of neuropsychiatric systemic lupus erythematosus with mental disorders - review of the literature] |
| Q89356063 | [The value of brain magnetic resonance imaging in the early diagnosis of neuropsychiatric systemic lupus erythematosus] |
| Q3634866 | Lupus headache | subclass of | P279 |
| Arabic (ar / Q13955) | ذئبة حمامية جهازية عصبية نفسية | wikipedia |
| Neuropsychiatric systemic lupus erythematosus | wikipedia | |
| Neurolupus | wikipedia | |
| NPSLE | wikipedia | |
| Toczeń neuropsychiatryczny | wikipedia |
Search more.